Last reviewed · How we verify
Anaferon for Children
Anaferon for Children is an immunomodulatory agent that stimulates interferon production and enhances innate immune responses to combat viral infections.
Anaferon for Children is an immunomodulatory agent that stimulates interferon production and enhances innate immune responses to combat viral infections. Used for Acute viral infections in children (influenza, ARVI, herpes simplex), Prophylaxis of viral infections in pediatric patients.
At a glance
| Generic name | Anaferon for Children |
|---|---|
| Also known as | Anaferon for Children in tablets |
| Sponsor | Materia Medica Holding |
| Drug class | Immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Immunology / Virology |
| Phase | FDA-approved |
Mechanism of action
The drug contains highly diluted antibodies to human interferon gamma that are believed to act as an immune modulator, promoting the body's own interferon production and enhancing natural killer cell activity. It is used primarily in pediatric viral infections to support the immune system's antiviral defenses. The exact molecular mechanism remains incompletely characterized in conventional pharmacological terms.
Approved indications
- Acute viral infections in children (influenza, ARVI, herpes simplex)
- Prophylaxis of viral infections in pediatric patients
Common side effects
Key clinical trials
- Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI (PHASE4)
- Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children (PHASE4)
- Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anaferon for Children CI brief — competitive landscape report
- Anaferon for Children updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI